First Time Loading...

JW (Cayman) Therapeutics Co Ltd
HKEX:2126

Watchlist Manager
JW (Cayman) Therapeutics Co Ltd Logo
JW (Cayman) Therapeutics Co Ltd
HKEX:2126
Watchlist
Price: 1.83 HKD 0.55% Market Closed
Updated: Mar 28, 2024

Intrinsic Value

JW (Cayman) Therapeutics Co Ltd's intrinsic value estimate is unreliable because it is based only on its multiples and doesn't use a DCF valuation.

JW (Cayman) Therapeutics Co. Ltd. operates as a clinical stage cell therapy platform company. [ Read More ]

The intrinsic value of one JW (Cayman) Therapeutics Co Ltd stock under the Base Case scenario is 8.17 HKD. Compared to the current market price of 1.83 HKD, JW (Cayman) Therapeutics Co Ltd is Undervalued by 78%.

Key Points:
Intrinsic Value
Base Case
8.17 HKD
Undervaluation 78%
Intrinsic Value
Price
Worst Case
Base Case
Best Case

Valuation Backtest
JW (Cayman) Therapeutics Co Ltd

Backtest JW (Cayman) Therapeutics Co Ltd Intrinsic Value
Dive into the past to invest in the future

Run backtest to discover the historical profit from buying and selling JW (Cayman) Therapeutics Co Ltd stocks based on their intrinsic value.

Analyze the historical link between intrinsic value and market price to make more informed investment decisions.

Run Backtest
Settings
Valuation Methods
Buy/Sell Thresholds
Buy When:
%
Sell When:
%
B
S
Run Backtest
How does it work?

Fundamental Analysis

Financials

Balance Sheet Decomposition
JW (Cayman) Therapeutics Co Ltd

Current Assets 1.3B
Cash & Short-Term Investments 1.3B
Receivables 18.1m
Other Current Assets 50.2m
Non-Current Assets 1.3B
PP&E 371.6m
Intangibles 916.7m
Other Non-Current Assets 22.9m
Current Liabilities 348.6m
Accounts Payable 6.8m
Accrued Liabilities 44.2m
Other Current Liabilities 297.5m
Non-Current Liabilities 163.4m
Long-Term Debt 163.4m
Efficiency

Earnings Waterfall
JW (Cayman) Therapeutics Co Ltd

Revenue
167.4m CNY
Cost of Revenue
-87m CNY
Gross Profit
80.4m CNY
Operating Expenses
-745.2m CNY
Operating Income
-664.8m CNY
Other Expenses
-132.5m CNY
Net Income
-797.3m CNY

Free Cash Flow Analysis
JW (Cayman) Therapeutics Co Ltd

Last Value
3-Years Average
FCF Margin
Conversion Rate
History
Components
Chart
Table
What is Free Cash Flow?
Fundamental Scores

Profitability Score
Profitability Due Diligence

JW (Cayman) Therapeutics Co Ltd's profitability score is 27/100. The higher the profitability score, the more profitable the company is.

Exceptional Revenue Growth Forecast
Exceptional 1-Year Revenue Growth
ROE is Increasing
Positive Gross Profit
27/100
Profitability
Score

JW (Cayman) Therapeutics Co Ltd's profitability score is 27/100. The higher the profitability score, the more profitable the company is.

Solvency Score
Solvency Due Diligence

JW (Cayman) Therapeutics Co Ltd's solvency score is 55/100. The higher the solvency score, the more solvent the company is.

Long-Term Solvency
Negative Net Debt
Short-Term Solvency
Low D/E
55/100
Solvency
Score

JW (Cayman) Therapeutics Co Ltd's solvency score is 55/100. The higher the solvency score, the more solvent the company is.

Wall St
Price Targets

Price Targets Summary
JW (Cayman) Therapeutics Co Ltd

Wall Street analysts forecast JW (Cayman) Therapeutics Co Ltd stock price to rise over the next 12 months.

According to Wall Street analysts, the average 1-year price target for JW (Cayman) Therapeutics Co Ltd is 3.43 HKD with a low forecast of 2.93 HKD and a high forecast of 4.01 HKD.

Lowest
Price Target
2.93 HKD
60% Upside
Average
Price Target
3.43 HKD
87% Upside
Highest
Price Target
4.01 HKD
119% Upside
View Analyst Estimates
View Analyst Estimates

Competitive Landscape

Shareholder Return

Price
JW (Cayman) Therapeutics Co Ltd

1M 1M
-9%
6M 6M
-11%
1Y 1Y
-50%
3Y 3Y
-94%
5Y 5Y
-92%
10Y 10Y
-92%
Annual Price Range
1.83
52w Low
1.61
52w High
3.84
Price Metrics
Average Annual Return -31.64%
Standard Deviation of Annual Returns 46.71%
Max Drawdown -97%
Shares Statistics
Market Capitalization 740.6m HKD
Shares Outstanding 411 535 008
Percentage of Shares Shorted
N/A

Return Decomposition
Main factors of price return

What is price return decomposition?

Company Profile

JW (Cayman) Therapeutics Co Ltd Logo
JW (Cayman) Therapeutics Co Ltd

Country

China

Industry

Biotechnology

Market Cap

740.6m HKD

Dividend Yield

0%

Description

JW (Cayman) Therapeutics Co. Ltd. operates as a clinical stage cell therapy platform company. The company is headquartered in Shanghai, Shanghai. The company went IPO on 2020-11-03. The firm is focuses on developing cell therapies for the China market to transform the treatment of cancer for Chinese patients. Through its subsidiary, it has built an integrated platform focused on developing, manufacturing and commercializing breakthrough cell-based immunotherapies for hematological cancers and solid tumors. Its main product candidate, relmacabtagene autoleucel (relma-cel), is an autologous anti-CD19 CAR-T therapy for relapsed or refractory (r/r) B-cell lymphoma. The firm mainly conducts its businesses in the China market.

Contact

SHANGHAI
Shanghai
4F, Building 42, No. 225 Meisheng Road, Pilot Free Trade Zone
http://www.jwtherapeutics.com/

IPO

2020-11-03

Employees

477

Officers

Co-founder, Executive Chairman of the Board & CEO
Dr. Yiping Li M.D.
Senior Vice President of Tech Operations
Cao Xiaoping Ph.D.
Senior VP & Chief Scientific Officer
Dr. Shaun Paul Cordoba Ph.D.
Senior Vice President of Corporate Development
Mr. Raymond J. Hage Jr.
Senior VP & Chief Commercial Officer
Mr. Qiong Wu
Senior Advisor & Acting Chief Medical Officer
Mr. Mark J. Gilbert M.D.
Show More
Company Secretary
Ms. Ka Man Ng A.C.I.S., A.C.S.
Show Less

See Also

Discover More
What is the Intrinsic Value of one JW (Cayman) Therapeutics Co Ltd stock?

The intrinsic value of one JW (Cayman) Therapeutics Co Ltd stock under the Base Case scenario is 8.17 HKD.

Is JW (Cayman) Therapeutics Co Ltd stock undervalued or overvalued?

Compared to the current market price of 1.83 HKD, JW (Cayman) Therapeutics Co Ltd is Undervalued by 78%.